The ideal AntiCoagulant Drug

In Special Issue 3 of 2013 J. Harenberg, S. Zolfaghari and C. Weiss (Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany) described the ideal AntiCoagulant Drug.

Related items

Analytical Information : 1

Cases : 1

Guidelines : 2

Quality Issues : 1

Analytical Information

Assays

Cases

ECAT Documentation

Guidelines

Haemostatic Cascade

Parameter

Quality Issues

Surveys and Studies

Terminology

The ideal AntiCoagulant Drug

Related items

Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays

Acquired Hemophilia A, case study

ICSH Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

Update Recommendations for Laboratory Measurement of Direct Oral Anticoagulants, ICSH recommendations

External quality assessment for Rivaroxaban and Dabigatran

Clotpedia

© 2022 ECAT Clotpedia All Rights Reserved

ECAT Foundation
P.O. Box 107
2250 AC Voorschoten | The Netherlands
Email: info@ecat.nl
T: +31 (0) 71 3030 910 | F: +31 (0) 71 3030 919

Clotpedia Support Form

Success

The ideal AntiCoagulant Drug

Related items

Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays

Acquired Hemophilia A, case study

ICSH Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

Update Recommendations for Laboratory Measurement of Direct Oral Anticoagulants, ICSH recommendations

External quality assessment for Rivaroxaban and Dabigatran

Clotpedia

© 2022 ECAT Clotpedia All Rights Reserved

ECAT Foundation P.O. Box 107 2250 AC Voorschoten | The Netherlands Email: info@ecat.nl T: +31 (0) 71 3030 910 | F: +31 (0) 71 3030 919

ECAT Foundation
P.O. Box 107
2250 AC Voorschoten | The Netherlands
Email: info@ecat.nl
T: +31 (0) 71 3030 910 | F: +31 (0) 71 3030 919